David Sterman has worked as an investment analyst for nearly two decades. He started his Wall Street career in equity research at Smith Barney, culminating in a position as Senior Analyst covering European banks. While at Smith Barney, he learned of all the tricks used by Wall Street to steer the best advice to their top clients and their own trading desk.
David has also served as Managing Editor at TheStreet.com and Director of Research at Individual Investor. In addition, David worked as Director of Research for Jesup & Lamont Securities. David has made numerous media appearances over the years, primarily on CNBC and Bloomberg TV, and has a master's degree in management from Georgia Tech.
David Stermanon
Analyst Articles
After a steady six-month surge, the stock markets are reversing course. The S&P 500 is off roughly 5% since early April, and signs are emerging that there may be plenty more downside on the way. The problems for Greece — and Europe — keep mounting. The continent’s major economies have… Read More
High unemployment and slow economic growth are hardly conditions under which most companies thrive. But I’ve discovered an industry that is doing just that. In fact, my favorite stock in this space saw annual sales gains of 8.5% in 2009, 15% in 2010 and 19% in 2011 while many other… Read More
Investors have been fretting about a weaker economy and the implications for economically-sensitive assets such as steel, copper, iron ore and other commodities. Indeed, the underlying spot prices for several key commodities are at multi-year lows and… Read More
In this low interest rate environment, investors have turned to high-yielding blue-chips as a source of retirement income. This five-part series will outline what I believe to be the top five dividend aristocrat stocks, most suitable for a retiree’s portfolio. My first three articles in our five-part series on… Read More
Cooler heads have prevailed. A showdown between the executive branch of government and the judicial branch of government looked to usher in a new era of intra-governmental rancor that our Founding Fathers sought to avoid. But the Supreme Court’s decision to let much of the Obama Administration’s health care law… Read More
“There’s no question that the earth is going to run out of oil within the next 10 years”, read the Peak Oil investment pitch that came across my desk. Citing a variety of scientists and academics, it appeared that these guys really did their homework when preparing the presentation. It… Read More
During the past two decades, management teams at virtually every major U.S. company have identified plans to move into foreign markets. Whereas in terms of population and purchasing power, the European market offers the same opportunity as the U.S. market,… Read More
I’ll never forget trading during the Internet boom of the late 1990s. Internet-related stocks would sometimes jump two or more points at a time, from tick to tick, as crazed investors just poured money into the latest big thing. Even stocks with no revenue and a questionable business plan would… Read More
Biotech investing is awfully tricky. For every stock pick that performs well, a number of others blow up. From increasingly tough hurdles with clinical trials to the mercurial rulings of the Food & Drug Administration (FDA), it’s a field littered with landmines. And it often requires deep medical knowledge to… Read More
Many investors make buy or sell decisions based on analyst recommendations about stocks, but this isn’t always a smart strategy. While it’s true analysts spend more time than the rest of us studying company data, at the end of the day, it still comes down to individual opinions, and it’s… Read More
